Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
IHC, IHC - Paraffin, Western blot, Immunoprecipitation
Mouse Monoclonal (IgG) to Human TCF7
IHC, ICC, Western blot
Human (tested or 100% immunogen sequence identity)
Protein G purified
Specificity and Use
TCF7 antibody was raised against maltose binding protein (MBP) fusion protein corresponding to residues 102-269 of human TCF-1A splice variant. The epitope maps to a region just N-terminal to the High Mobility Group (HMG) box
Recognizes multiple splice isoforms of TCF-1. The epitope maps to a region just N-terminal to the High Mobility Group (HMG) box.
0.2 M Tris-glycine, pH 7.5, 0.15 M sodium chloride, 0.05% sodium azide
Store at -20°C. Aliquot to avoid freeze-thaw cycles. Store undiluted.
Transcriptional activator involved in T-cell lymphocyte differentiation. Necessary for the survival of CD4+ CD8+ immature thymocytes. Isoforms lacking the N-terminal CTNNB1 binding domain cannot fulfill this role. Binds to the T-lymphocyte-specific enhancer element (5'-WWCAAAG-3') found in the promoter of the CD3E gene. May also act as feedback transcriptional repressor of CTNNB1 and TCF7L2 target genes. TLE1, TLE2, TLE3 and TLE4 repress transactivation mediated by TCF7 and CTNNB1.